Diabetes mellitus, type 2 Trials in Killeen, United States
Conditions / Diabetes mellitus, type 2 / Killeen, United States
Diabetes mellitus, type 2 is a medical condition with active clinical research programs worldwide.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00104182 | Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes | COMPLETED | PHASE3 |
| NCT01183013 | 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks | COMPLETED | PHASE3 |
| NCT00279201 | The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) | COMPLETED | PHASE4 |
| NCT01068665 | Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes | COMPLETED | PHASE3 |
| NCT01336023 | Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes | COMPLETED | PHASE3 |
| NCT02730377 | Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes | COMPLETED | PHASE4 |
| NCT01137812 | The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial) | COMPLETED | PHASE3 |
| NCT01159600 | Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes | COMPLETED | PHASE3 |
| NCT01326026 | Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus | COMPLETED | PHASE3 |
| NCT01289990 | Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes | COMPLETED | PHASE3 |